Search Medical Condition
Please enter condition
Please choose location
 

Palisades Park, New Jersey Clinical Trials

A listing of Palisades Park, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (3185) clinical trials

A Phase 3 Study to Evaluate ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Phase

0.18 miles

Learn More »

Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis in participants failing treatment for active noninfectious uveitis.

Phase

0.18 miles

Learn More »

A Study of AK002 in Patients With Atopic Keratoconjunctivitis Vernal Keratoconjunctivitis and Perennial Allergic Conjunctivitis

This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion, at up to 1 mg/kg for 6 doses.

Phase

0.18 miles

Learn More »

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome (SBS) Who Completed TED-C14-006

This study will follow subjects who completed the TED-C14-006 study. The purpose of this study is to evaluate the long-term safety and efficacy of teduglutide in pediatric subjects with Short Bowel Syndrome (SBS). This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C14-006.

Phase

1.72 miles

Learn More »

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients age 6-11 will receive oral liquid formulation ...

Phase

2.67 miles

Learn More »

ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Earlier adjuvant or neoadjuvant treatment for more limited disease is allowed, but not included in the "at least two ...

Phase

2.67 miles

Learn More »

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide Each Given With Radiation Therapy for Newly-diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy ...

Phase

2.67 miles

Learn More »

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

Despite advances in early detection and therapeutic options, unresectable or metastatic breast cancer remains incurable and is one of the leading causes of cancer-related mortality. Breast cancer is a molecularly heterogeneous disease. This study will be evaluating estrogen receptor (ER) expression positivity and/or progesterone receptor (PgR) positivity of breast cancer ...

Phase

2.67 miles

Learn More »

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BAY 1251152 in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).

Phase

2.67 miles

Learn More »

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Protocol PEN-221-001 will first enroll patients into a dose escalation phase, where a Bayesian logistic regression model, guided by the escalation with overdose control principle and overseen by a safety review committee, will be used to make dose recommendations and estimate the maximum tolerated dose (MTD). Once the MTD has ...

Phase

2.67 miles

Learn More »